Below are the financial statements of Denali Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 as of 2024-12-31 | 2023 as of 2023-12-31 |
|---|---|---|
| Assets | — | — |
| Current assets | — | — |
| Cash and cash equivalents | 174.96a | 127.11a |
| Short-term marketable securities | 657.37a | 907.41a |
| Prepaid expenses and other current assets | 32.11a | 29.63a |
| Total current assets | 864.44a | 1,064.14a |
| Long-term marketable securities | 359.37a | 0a |
| Property and equipment, net | 55.24a | 45.59a |
| Finance lease right-of-use asset | 47.53a | 0a |
| Operating lease right-of-use asset | 22.86a | 26.05a |
| Other non-current assets | 24.74a | 18.14a |
| Total assets | 1,374.18a | 1,153.92a |
| Liabilities and stockholders’ equity | — | — |
| Current liabilities | — | — |
| Accounts payable | 11.14a | 9.48a |
| Accrued expenses and other current liabilities | 91.07a | 68.5a |
| Total current liabilities | 102.21a | 77.98a |
| Operating lease liability, less current portion | 36.67a | 44.98a |
| Finance lease liability, less current portion | 5.62a | 0a |
| Total liabilities | 144.5a | 122.96a |
| Stockholders’ equity | — | — |
| Convertible preferred stock | 0a | 0a |
| Common stock | 1.77a | 1.71a |
| Additional paid-in capital | 2,764.88a | 2,144.81a |
| Accumulated other comprehensive income | 2.02a | 0.64a |
| Accumulated deficit | -1,538.98a | -1,116.21a |
| Total stockholders’ equity | 1,229.68a | 1,030.95a |
| Total liabilities and stockholders’ equity | 1,374.18a | 1,153.92a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Denali Therapeutics’s data sources below and access millions more through our Disclosure Search.